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1. Introduction
Obsessive-compulsive disorder (OCD) is a chronic condition represented by a diverse group
of symptoms that include intrusive thoughts, rituals, preoccupations, and compulsions. These
recurrent obsessions or compulsions cause severe distress to the person. The obsessions or
compulsions are time-consuming and interfere significantly with the person's normal routine,
occupational functioning, usual social activities, or relationships [1].
In the 10th revision of International Statistical Classification of Diseases and Related Health
Problems (ICD-10), OCD is diagnosed when either obsessions or compulsions (or both) are
present for a period of at least 2 weeks, acknowledged as excessive or unreasonable and are
repetitive and unpleasant. The patient tries to resist them and acknowledges that they are
originating in the mind and are not imposed by outside persons or influences as well as the
obsessive thought or the compulsive act is not experienced as pleasurable. [2] Recently
American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental
Disorders, DSM-5 separated it from anxiety disorder group and reclassified it with disorders
like Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania, and excoriation
disorder [3].
A few decades ago OCD had been regarded as a psychiatric condition that was mostly
treatment-refractory [4]. Modern pharmacotherapy for OCD began with the observation that
colmipramine but not other TCAs, relieved OC symptoms. This led to hypothesis that
serotonin might be involved in pathophysiology of OCD5. Also numerous investigations
showing the therapeutic action of different selective serotonin reuptake inhibitors (SSRIs) in
OCD, and by additional findings, such as the provocation of OCD symptoms by the seroto‐
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nergic agent m-chlorophenylpiperazine the role of serotonergic system in OCD was further
made strong. Not only is serotonin uptake blockade an apparent prerequisite for clinical
improvement, but there is a correlation between the magnitude of clinical response and the
reduction in various serotonin markers during treatment with these drugs [6]. There is
substantial evidence that suggests OCD patients may benefit from addition of antipsychotics
to their ongoing SSRI treatment, suggesting that dopamine also might play a role in the
pathophysiology of OCD [7]. Latest neuroimaging techniques have shown various structural
and volumetric abnormalities in prefrontal and basal ganglia region in patients suffering from
OCD. In prefrontal cortex there may be dopaminergic hyperfunction and in basal ganglia there
may be hypofunction of serotonergic system. This dysfunction of the 'cortico-striato-thalamic'
loops is strongly linked to the symptoms of OCD, where the dopamine has an inhibitory effect
on GABA neurons. The ascending serotonergic projections from the raphe nuclei restrain and
control the function of these loops. Thus, when serotonergic hypofunction is present, the
predominantly dopaminergic loops became overactive, which has been confirmed by neuro‐
imaging techniques and by neurocognitive tests as well. This could be the reason for the fact
that SSRIs have limited success in the treatment of OCD symptoms [8]. The role of glutamate,
which is the primary excitatory neurotransmitter, is being increasingly investigated in the
pathophisiology of OCD [9]. Glutamate is major excitatory neurotransmitter in the cortico-
striatal-pallido-thalamocortical circuits and is also known to interact extensively with seroto‐
nin and dopamine [10]. Moore et al. (1998) reported striking changes in caudate glutamatergic
concentrations (Glx)-a marker for combined glutamate and glutamine, resonance on proton
magnetic resonance spectroscopy (1H-MRS) in a paediatric OCD patient following treatment
with Paroxetine [11]. Rosenberg et al. (2000) studied 11 psychotropic drug-naïve children with
OCD, with single-voxel 1H-MRS examinations and demonstrated that caudate Glx concen‐
trations were significantly greater in the patients compared to healthy controls [12]. They also
found that the caudate Glx levels in patients decreased significantly following 12-weeks
treatment with Paroxetine to levels comparable to that of controls and the decrease was
associated with decrease in symptom severity of the OCD patients, while there was no
difference in Glx levels in the occipital cortex between the two groups. Whiteside et al. (2006)
have demonstrated that within the right orbitofrontal white matter, relative levels of Glx and
N-acetylaspartate were increased in adult patients with OCD compared with healthy controls
and greater levels of Glx/Creatine were associated with more severe OCD symptoms. [13]
Evidences from genetic studies are also suggesting the role of glutamate in pathophsiology of
OCD. Investigators have reported statistically significant association between OCD and a locus
on chromosome 9p24 that codes for a high-affinity neuronal/epithelial excitatory amino acid
transporter (EAAC-1), also known as SLC1A1 (Solute carrier family 1, member 1) [14, 15]. It is
hypothesized that in the brain this transporter is crucial in terminating the action of the
excitatory neurotransmitter glutamate and in maintaining extracellular glutamate concentra‐
tions within a normal range [16].Researchers have examined the role of the opioid system and
neuropeptides like oxytocin and vasopressin in OCD although the evidence has been equivocal
[17, 18, 19].
About 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate
courses of treatment with serotonin reuptake inhibitors (SRI) and even to combination of
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medicines [20]. Those OCD patients who do not achieve a satisfactory response after an
adequate trial of first line therapies are described as treatment resistant. The satisfactory
response is usually defined by a reduction in the Yale-Brown Obsessive Compulsive scale score
≥35% or ≥25% with respect to baseline [21].
The first selective serotonin reuptake inhibitor (SSRI), fluoxetine, was introduced in 1987. This
was followed by other SSRI’s i.e.fluvoxamine, paroxetine, sertraline, citalopram and escitalo‐
pram. The SSRIs are each structurally and chemically distinct. Escitalopram, an isomer of
citalopram, is the only exception. This molecular diversity explains why individual responses
to, and tolerability of, SSRIs are so varied. Fluoxetine has the longest half-life: 4 to 6 days. The
half-life of sertraline is 26 hours, 35 hours for citalopram, 27 to 32 hours for escitalopram, 21
hours for paroxetine, and 15 hours for fluvoxamine. Sertraline, fluoxetine, and paroxetine
being the most highly bound and escitalopram being the least bound. All SSRIs are metabolized
in the liver by the cytochrome P450 enzymes. The most important drug-drug interactions
involving the SSRIs occur as a result of the SSRIs inhibiting the metabolism of a co administered
medication [1]. Citalopram and escitalopram are the most selective inhibitors of serotonin
reuptake, with very little inhibition of norepinephrine or dopamine reuptake and very low
affinities for histamine H1, GABA or benzodiazepine receptors. The other SSRIs have a similar
profile, except that fluoxetine weakly inhibits norepinephrine reuptake and binds to 5-HT2C
receptors; sertraline weakly inhibits norepinephrine and dopamine reuptake; and paroxetine
has significant anticholinergic activity at higher dosages and binds to nitric oxide synthase [1].
According to a large number of published randomized controlled trials (RCTs), meta-analyses,
current expert guidelines, and consensus statements, SSRIs and clomipramine are recom‐
mended as first-line agents for drug treatment of OCD [22, 23, 24, 25]. Guidelines of the World
Federation of Societies of Biological Psychiatry (WFSBP) for the pharmacological treatment of
OCD grant the highest category of evidence (“A”, ie, full evidence from several RCTs) for the
SSRIs escitalopram, fluvoxamine, fluoxetine, paroxetine, and sertraline, as well as for the TCA
clomipramine. Since clomipramine is less well tolerated than the SSRIs, it was given a
recommendation grade of 2 (moderate risk benefit ratio), while the SSRIs received the highest
recommendation grade 1 (good risk: benefit ratio). For citalopram a recommendation grade
of 3 (limited evidence from controlled studies) was given as only one positive double-blind,
placebo-controlled study was published. According to WFSBP guidelines usually lower
response rates are achieved in OCD in comparison with other anxiety disorders, and that
sometimes only partial remission is achieved and higher doses are required for these drugs in
OCD than for other anxiety disorders. In a systematic review of all long-term, placebo-
controlled trials with SSRIs in OCD, the likelihood of relapse during 24 to 52 weeks of treatment
was significantly lower on an SSRI than with placebo [26].
According to the British National Institute for Health and Clinical Excellence (NICE) and the
Royal College of Psychiatrists guidelines, the initial pharmacological treatment in adults with
OCD should be one of the following SSRIs: fluoxetine, fluvoxamine, paroxetine, sertraline, or
citalopram [27]. A Cochrane review of placebo-controlled SSRI trials in OCD, comprising 17
studies with 3097 participants showed efficacy for all SSRIs (citalopram, fluoxetine, fluvoxa‐
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mine, paroxetine, and sertraline) but no statistical differences in short-term therapeutic action
among the individual SSRIs [28].
2. Treatment of OCD patients refractory to serotonergic antidepressants
Although SSRIs and clomipramine have proven efficacy in OCD, about 40% to 60% of pa‐
tients show no or just partial symptom improvement to a treatment with a first-line drug [29].
The large fraction of patients without substantial response to standard treatment experiences
significant morbidity [30]. Response is typically operationalized as a decline in symptoms, as
measured by a 30–35% reduction in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [31,
32] or a decline in symptoms below a threshold of 16 (i.e., the boundary between mild and
moderate OCD symptoms). So those patients who are “treatment responsive” as per operation‐
alized criterion may continue to have levels of symptoms in the mild-moderate range and spend
hours daily preoccupied with their obsessions and compulsions. We need novel treatment
modalities for these partially responsive as well as treatment resistant patients with OCD.
High-dose treatment with serotonergic drugs is one of the available strategy which should be
considered first. Greater improvement with higher vs lower doses of SSRI was reported using
250 to400 mg/d vs 200 mg/d of sertraline [33]and with escitalopram after an increase of dose
from 20 up to 50 mg/d [34]. In a Open-label study of high (30 mg) and moderate (20 mg) dose
escitalopram for the treatment of obsessive-compulsive disorder by Dougherty et al found that
the 30 mg (vs. 20 mg) dose of escitalopram may provide a superior reduction in OCD symptoms
for those sufferers with comorbid depression and/or anxiety [35].
Studies with tricyclic antidepressants, which act on both serotonin and norepinephrine,
suggested that blockade of serotonin reuptake was required for antiobsessional effect [36]. In
a meta-analysis of studies by Geller et al., including over 1000 adolescents with OCD clomipr‐
amine was shown to have greater efficacy compared with fluoxetine, fluvoxamine, paroxetine,
and sertraline [37]. Clomipramine, which retains some norepinephrine reuptake inhibitory
(NRI) effect relative to the SSRIs and its metabolite desmethylclomipramine has significant
NRI activity, appears to be more effective than the more selective agents in meta analyses,
though not in head-to-head comparisons leads to the hypothesis that dual-acting agent might
be more effective in treatment- resistant patients [38]. An open-label trial of venlafaxine, which
is a dual acting agent, both in treatment- naive and treatment-resistant OCD, suggested
superior efficacy to SSRIs [39], In a head-to-head comparison between venlafaxine and
clomipramine suggested comparable efficacy to clomipramine. [40]
Another strategy is to use other agents that target the serotonin system in a different way.
Mirtazapine, a 5HT2A agonist, can accelerate the effect of paroxetine on OCD symptoms [41].
But the long-term benefit of mirtazepine and citalopram augumentation over citalopram alone
is unclear [42]. Mirtazapine has also been shown to be efficacious as monotherapy in OCD
patients in an open trial [43].
Intravenous clomipramine [44, 45] and intravenous citalopram [46] have been shown to lead
to a substantial improvement in symptoms in some treatment-resistant patients.
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3. Augmentation with other drugs
A number of different agents are being used as augmentation strategies for standard SRI
therapy in treatment- refractory OCD, with variable success. Agents with modes of action
beyond the serotonin system have shown the capacity to significantly improve symptoms in
patients with limited response to SRI therapy alone [47].
Tourette’s syndrome is highly comorbid with Obsessive-compulsive disorder in the pediatric
population [48]. Overlapping pathological changes in the basal ganglia are implicated in the
two disorders [49, 50]. As we see both typical and atypical antipsychotics have positive effects
in Tourette’s syndrometrials of dopamine antagonists, augmentation therapy in OCD might
be worth considering [51, 52].
The combination of the antipsychotics risperidone, haloperidol, olanzapine, or quetiapine with
an SSRI was shown to be more effective than SSRI monotherapy in treatment-resistant cases
and is recommended (grade 3, ie, limited evidence from controlled studies) by the WFSBP
guidelines [25]. Antipsychotics should be added after at least 3 months of maximally tolerated
therapy of an SSRI. Response usually commences within one month duration as seen in most
of the studies and about one third of treatment-refractory OCD patients show a clinically
meaningful improvement. Superior effects of quetiapine versus ziprasidone as an adjunct to
SSRI were found in treatment-resistant OCD patients in a retrospective study [53]. A single-
blind study comparing risperidone versus olanzapine augmentation of SSRIs showed positive
responses without differences between the two treatment groups [54]. In a 12-week, open-
label, trial of aripiprazole, significant improvement of OCD symptoms was demonstrated [55].
In a small, open-label study suggest that aripiprazole as monotherapy was helpful for treating
OCD [56].Augmentation of paroxetine with perospirone resulted in improvement in a case
report [57].
A smaller number of studies have examined the utility of augmentation therapy with opioid
agents. Morphine given once weekly has shown efficacy in treatment-resistant obsessive-
compulsive disorder in a single doubleblind study, and administration of the opioid agonist
tramadol hydrochloride has also been shown to diminish OCD symptoms [58, 59, 60].The
mechanism of this interesting effect is unknown, but one of the proposed mechanism being
opioids inhibiting glutamate release in cortex through disinhibition of serotonergic neurons.
Other augmentation agents include clonazepam, inositol, clonidine, monoamine oxidase
inhibitors, and antiandrogens [61].
Positive results have been reported with longterm augmentation with citalopram (up to 60
mg/d) in 20 treatment-resistent OCD patients on clomipramine [62].
Riluzole is an antiglutamatergic agent that is approved by the Food and Drug Administration
for neuroprotection in amyotrophic lateral sclerosis (ALS) [63]. Various proposed mechanisms
of action of riluzole are inhibition of sodium currents in glutamatergic axon terminals, reducing
neurotransmitter release [64]; reduction of P/Qtype calcium currents in the axon terminals,
with a similar effect on glutamate release [65]; extension of the open time of Kv1.4 potassium
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channels [66]; and increased astrocytic uptake of glutamate [67]. A case report and an open
label study suggest augmentation with the antiglutamatergic agent riluzole in SRI-resistant
OCD patients has significant efficacy [68, 69].
The amino acid N-acetylcysteine (NAC) is widely used for its antioxidant properties and as
an antidote for acetaminophen toxicity. Preclinical studies suggest that NAC also modulates
CNS glutamate. NAC is converted to cystine, a substrate for the glutamate/ cystine antiporter
located on glial cells. The uptake of cystine by glia causes glial release of glutamate into the
extrasynaptic space, where it appears to stimulate inhibitory metabotropic glutamate receptors
on glutamatergic nerve terminals and thereby reduces the synaptic release of glutamate
[70].There is evidence for benefit of NAC augmentation to SSRI’s in treating SRI-refractory
OCD in two preliminary case reports [71, 72].
In an open-label augmentation trial with memantine, an N-methyl-Daspartate (NMDA)
glutamate receptor antagonist, improvement of symptoms was seen in about half of the
patients, who had failed to respond to treatment with an SSRI for at least 3 months [73]. Feusner
et al in 2009 in an open label trial, compared the differential efficacy of memantine for
obsessive-compulsive disorder vs. generalized anxiety disorder. Ten OCD and 7 GAD subjects
received 12 weeks of open-label memantine 10 mg twice daily, as either monotherapy or
augmentation of their existing medication. Primary outcome measures were the Yale-Brown
Obsessive Compulsive Scale ( YBOCS) for the OCD group, the Hamilton Anxiety Rating Scale
(HARS) for the GAD group, and the Clinical Global Impression-Improvement Scale (CGII) for
both groups. The results suggest that memantine may have preferential efficacy in the
treatment of OCD versus GAD. But further larger placebo controlled studies are required
[74].A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive
Disorder provides preliminary supportive evidence for the effectiveness of memantine as a
glutamatergic augmenting agent in severe OCD [75].
Adjunctive glycine (an NMDA glutamate receptor agonist) was also tested in a small double-
blind placebo-controlled trial and approached efficacy for treatment of OCD symptoms but
with high dropout rates [76].
Amantadine (another NMDA antagonist) could be a useful drug for the treatment of OCD
according to preclinical findings [77].
Augmentation of SSRI’s with topiramate, in treatment-resistant OCD patients may be benefi‐
cial [78, 79]. Double-blind studies with topiramate are being conducted [80].
Pregabalin, which can indirectly inhibit glutamate release via blockade of calcium channels,
beneficial effects on OCD symptoms in combination with serotonergic antidepressants have
been reported in case reports [81, 82].A double-blind placebo-controlled study with pregablin
in SSRI-refractory OCD is being conducted [83].
D-cycloserine (a glutamatergic partial N-methyl-d-aspartate (NMDA) agonist) augmentation
of psychotherapy with exposure and response prevention in OCD has so far been investigated
in three randomized, double-blind, placebo-controlled studies. Significantly greater decreases
in obsession-related distress after four exposure sessions under D-cycloserine (125 mg, given
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2 hours before each session) were reported, however, after additional sessions, the placebo
group tended to catch up [84]. In another study, OCD patients were reported to be significantly
more improved under D-cycloserine at mid-treatment (ten behavior therapy sessions in total,
dose of 100 mg 1 hour before each session), but not at later time points, and the D-cycloserine
group’s depressive symptoms were significantly more improved at posttreatment [85].
In a randomized, double-blinded, placebo-controlled augmentation trial examining CBT + D
cycloserine versus CBT + Placebo with 30 youth (aged 8–17) with a primary diagnosis of OCD
received seven exposure and response prevention sessions paired with DCS or placebo taken
1 hour before sessions. Compared with the CBT + Placebo group, youth in the CBT + D
cycloserine arm showed small-to-moderate treatment effects. These results provide initial
support for a more extensive study of D Cycloserine augmentation of CBT among youth with
OCD [86].
It has been reported that canna-binoids inhibit glutamate release in the CNS. As discussed
above glutamate is implicated in pathophisiology of OCD. Addition-ally, cannabinoid type 1
(CB1) receptors are distributed abun-dantly in the striatum, a brain region frequently associ‐
ated with OCD [87, 88].
Two case reports showed Improvement in Refractory Obsessive Compulsive Disorder With
cannabinoid Dronabinol [89].
4. Augmentation with or switch to cognitive-behavioral psychotherapy
In a RCT, patients who were put on adequate dosages of SSRI for at least 12 weeks, and in
those who continued to have clinically significant symptoms, the augmentative effect of
exposure and ritual prevention versus stress management training was compared; Group with
exposure and response prevention had significant decrease of symptom severity of at least
25% by the end of 8 weeks [90].In a controlled open trial, patients with a history of an inade‐
quate response to multiple SSRI medications in adequate doses were treated with 15 sessions
of outpatient CBT. OCD symptoms decreased significantly and gains were maintained over 6
months [91]. A meta-analysis of psychotherapy and pharmacotherapy for OCD found highest
effect sizes for combined treatment [92].
5. Invasive treatment options
5.1. Psychosurgery
Treatment resistant obsessive-compulsive disorder is one of the few diagnoses in modern
psychiatry for which invasive neurosurgical procedures are part of the established treatment
options. All ablative neurosurgical techniques target the CSTC circuits that are believed to be
hyperactive in OCD. Anterior cingulotomy involves a lesion targeting the anterior cingulated
cortex and cingulum. Anterior capsulotomy targets the subcaudate white matter, interrupting
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frontothalamic fibers. Limbic leucotomy combines these two, lesioning both cingulum and
subcaudate white matter [93].
5.2. Deep brain stimulation
Several small-scale controlled and open studies have suggested that deep brain stimulation
(DBS) of the internal capsule and/or the adjacent ventral striatal region may be of benefit to
severely affected OCD patients who have exhausted conventional therapies [94, 95, 96, 97, 98,
99, 100, 101].
Benjamin et al in 2006 found promising long-term effects of DBS in highly treatment-resistant
OCD [102].
5.3. Electroconvulsive therapy (ECT)
Maletzky and colleagues in a retrospective study of 32 patients with treatmentresistant OCD
who received ECT between 1979 and 1991 (19 non-depressed and 13 depressed; 14 were
primarily checkers, 13 primarily cleaners, 4 did both). They were treated with bilateral
frontotemporal ECT and were evaluated 2 days prior to the start of treatment and at 5 days, 6
months, and 12 months after treatment. Five days after treatment, there were highly significant
differences between the pre- and post-scores (paired t-tests; P<.001). At 6-months posttreat‐
ment, the differences were still significant. In this study, ECT had an anti-obsessional effect
and the improvements occurred equally frequently and to an equal extent in depressed and
non-depressed groups [103]. In addition, several single-case reports provided further evidence
of the possible efficacy of ECT in treatment-resistant OCD. However, the unblinded design of
these reports, the frequent comorbidity with other Axis I psychopathology (schizophrenia,
depression, and Tourette’s syndrome), and the different parameters of ECT used limit the
confidence that can be placed in the findings [104, 105, [106, 107, 108].
5.4. Repetitive transcranial magnetic stimulation (rTMS)
Greenberg and colleagues randomized 12 patients with OCD into a singleblind trial. Patients
were treated with 1 session of active right-side, active left-side, or sham (occipital position)
TMS. Based on previous reports of prefrontal hypermetabolism or hyperperfusion in patients
with OCD,44 Greenberg and colleagues believed that the application of a highfrequency rTMS
to prefrontal cortex would have transiently interrupted OCD symptoms. The main finding
was that right prefrontal rTMS had modest acute effects on compulsions whereas effects of left
lateral prefrontal and occipital stimulation were transient and nonsignificant. Obsessions
appeared unaffected by rTMS. Treatment was well-tolerated, with two patients reporting mild
headache after stimulation [109]. Sachdev and colleagues randomized 12 treatment-resistant
OCD patients to a 10-session, single-blind, 2-week trial of active right-side or left-side TMS.
Ten subjects were taking medication (benzodiazepines, antidepressants, or antippsychotics)
and had been maintained on a constant dose for 8 weeks prior to and during the period of the
study. Evaluations after 2 weeks of stimulation and 1 month after the completion of the
treatment showed significant reduction in obsessions and compulsions in both groups with
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no significant difference between right and left stimulation on the overall Y-BOCS score. The
authors suggested that rTMS may be beneficial in the acute treatment of treatment resistant
OCD with an equal proportion of patients benefiting from right- and left-sided stimulation
[110]. In an open-label trial,10 patients with a history of several medication trial failures were
treated for 2 weeks with low-frequency TMS. The supplementary motor area (SMA) was
chosen as the site of stimulation with the coil placed along the sagittal midline in order to
stimulate the SMA bilaterally and simultaneously. The sample had a significant general clinical
improvement on the Clinical Global Impression Scale at the end of the first and second week
of treatment, and maintained that benefit at 1 month and 3 month follow-up [111]. Chiara
Ruffini and colleagues took twenty-three consecutively admitted right-handed inpatients with
DSM-IV-TR–diagnosed drug-resistant OCD and gave rTMS to the left OFC parallel (active: n
= 16) or perpendicular (sham: n = 7) to the scalp. The patients' OCD symptoms, mood, and
anxiety were rated at baseline, at the end of treatment, and once every 2 weeks for 3 months
after treatment. Considering changes in Yale-Brown Obsessive Compulsive Scale (YBOCS)
scores with 2-way analysis of variance for repeated measures for a total of 8 observations
(before rTMS, after treatment, and every 2 weeks for 12 weeks' follow-up), and found signif‐
icant reduction of YBOCS scores comparing active versus sham treatment for 10 weeks after
the end of rTMS (P <.02), with loss of significance after 12 weeks (P <.06). They concluded Low-
frequency rTMS of the left OFC produced significant but time-limited improvement in OCD
patients compared to sham treatment [112]. In a Randomized sham-controlled trial of repeti‐
tive transcranial magnetic stimulation in treatment-resistant obsessive–compulsive disorder
Antonio Mantovani et al found the response rate was 67% (6/9) with active and 22% (2/9) with
sham rTMS after 4 wk and patients receiving active rTMS showed on average a 25% reduction
in the YBOCS compared to a 12% reduction in those receiving sham. In those who received 8-
wk active rTMS, OCD symptoms improved from 28.2±5.8 to 14.5±3.6 [113].
Albert et al(2013) have most recently extensively reviewed available data on treatment resistant
OCD and attempted to build a treatment algorithm for those patients who fail to respond to a
first SSRI trial [114].
As WHO considers OCD to be fourth major mental illness with significant morbidity we need
more effective treatment options. Though a lot of research is available regarding evidence
based treatment approaches in treatment refractory OCD, a lot of clinical mysteries are still
present and further research need to be done. Most of the research available today is prelimi‐
nary short duration studies with small sample size and we need long term clinical trials to
further validate the hypothesis formed from these preliminary studies.
Serotonin related gene polymorphism is a field which might help in the prediction of response
to serotonergic drugs. Denys et al found that response in venlafaxine-treated OCD patients is
associated with the S/L genotype of the 5-HTTLPR polymorphism and in paroxetine-treated
OCD patients with the G/G genotype of the 5-HT2A polymorphism [115].
Functional imaging techniques for glucose metabolism might also predict treatment response
in patients with OCD. Saxena et al suggested that elevated activity (cerebral glucose metabo‐
lism) in the right caudate may be a marker of responsiveness to antiobsessional treatment [116].
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Metabotropic glutamate receptor anatagonists, are being developed by pharmaceutical
industry which might be of help in treatment resistant OCD patients [117, 118, 119].
Some of this exciting research may soon get translated into relevant clinical treatment options
for the patients suffering from continued agonizing symptoms of OCD.
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